Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Updated colorectal cancer screening guidelines

This article was originally published in The Gray Sheet

Executive Summary

The American Cancer Society, American College of Radiology and U.S. Multi-Society Task Force on Colorectal Cancer release joint consensus guidelines March 5 for colorectal cancer screening that add two new tests to those recommended for adults over 50 years old: stool-based DNA and CT colonography, also known as virtual colonoscopy. PreGen-Plus stool-based DNA assay developer Exact Sciences praised the health groups' decision. CMS on Jan. 30, however, proposed not to cover the screening test after the firm received a warning letter from FDA in October stating that PreGen-Plus needs to go through regulatory review ("1The Gray Sheet" Feb. 4, 2008, In Brief). The American College of Radiology is urging payers to reimburse appropriately for CT colonography as well. New data on the technology is expected to be published this spring (2"The Gray Sheet" Oct. 8, 2007, p. 17)

You may also be interested in...



Virtual Colonoscopy Catches CMS Eye; National Coverage Being Considered

The Medicare agency said May 19 it will consider providing national coverage for computed tomography colonography for cancer screening, a new technology that has gained visibility in recent months

Warning letter blocks DNA stool test coverage

CMS says Jan. 30 it will not cover Exact Science's PreGen-Plus assay as a screening alternative to colonoscopy because the test is no longer on the market. CMS decided to open a national coverage decision on the DNA stool test in August at Exact Science's request, but in October the firm received a 1warning letter from FDA stating that PreGen-Plus does not qualify as a lab-developed test and needs to undergo regulatory review (2"The Gray Sheet" Aug. 6, 2007, p. 9). In December, Exact Science asked CMS if it could withdraw its coverage request. "After a commercially available stool DNA test is cleared or approved by the FDA, a request for reconsideration would be anticipated," CMS says. The agency has until May to finalize its decision

NEJM Study Supports CT Colonography As Primary Colon Cancer Screen

Computed tomography imaging colonography may be a better method for primary colorectal cancer screening than optical colonoscopy, according to the authors of a study published Oct. 4 in the New England Journal of Medicine

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel